Novo Reports Wegovy Liver Marker Gains in Adults With MASH
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 8, 2026 Novo Nordisk has announced encouraging findings from a post-hoc...
GLP-1 receptor agonist
Advertisement
Novo Nordisk Reports Real-World Wegovy Benefits in MASH
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 6, 2026 Novo Nordisk has announced new real-world clinical findings showing...
MetaVia Reports 68% Liver Fat Reduction With DA-1726
Cambridge, Massachusetts, USA, November 5, 2026 MetaVia Inc. has announced promising interim clinical results demonstrating a statistically significant 68%...
Gan & Lee Reports Positive Bofanglutide Phase IIIb Data
Beijing, China, and Bridgewater, Massachusetts, United States, November 4, 2026 Gan & Lee Pharmaceuticals has announced positive topline results...
Ascletis Reports Strong ASC30 Phase 2 Diabetes Results
Hong Kong, China, October 29, 2026 Ascletis Pharma Inc. has announced positive topline results from its U.S. Phase 2...
Advertisements
Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
4Moving Biotech Targets Synovitis with Intra-Articular GLP-1 Therapy
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
Advertisement
